Holen Sie sich die Stockscreener-App
0.33
7.02%
-0.0249
Schlusskurs vom Vortag:
$0.3549
Offen:
$0.37
24-Stunden-Volumen:
24.16M
Relative Volume:
4.04
Marktkapitalisierung:
$3.01M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-17.41M
KGV:
-0.1003
EPS:
-3.29
Netto-Cashflow:
$-11.73M
1W Leistung:
-5.42%
1M Leistung:
-21.11%
6M Leistung:
-93.91%
1J Leistung:
-98.13%
1-Tages-Spanne:
$0.30
$0.3833
1-Wochen-Bereich:
$0.30
$0.3833
52-Wochen-Spanne:
$0.2848
$21.56
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Firmenname
Aptevo Therapeutics Inc
Sektor
Branche
Telefon
206-838-0500
Adresse
2401 4TH AVE., SEATTLE, WA
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-11-05 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-10-05 | Fortgesetzt | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Aktie (APVO) Neueste Nachrichten
APVO’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
APVO’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study - AccessWire
Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study - StockTitan
Should investors be concerned about APVO’s high price-to-sales ratio? - US Post News
Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024 - AccessWire
Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024 - Yahoo Finance
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024 - AccessWire
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024 - StockTitan
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024 - Yahoo Finance
Aptevo Therapeutics (NASDAQ:APVO) Now Covered by StockNews.com - Defense World
StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO) - Defense World
This trade activity should not be overlooked: Aptevo Therapeutics Inc (APVO) - SETE News
Balance Sheet Breakdown: Aptevo Therapeutics Inc (APVO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Can you still get a good price for Aptevo Therapeutics Inc (APVO) Shares at this point? - US Post News
Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update - Defense World
StockNews.com Initiates Coverage on Aptevo Therapeutics (NASDAQ:APVO) - Defense World
Contrasting Aptevo Therapeutics (NASDAQ:APVO) & Genprex (NASDAQ:GNPX) - Defense World
Aptevo Therapeutics Inc (APVO)’s stock rises to 0.44 per share - US Post News
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's What You Should Know - MSN
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Brokers Issue Forecasts for Aptevo Therapeutics Inc.’s Q3 2024 Earnings (NASDAQ:APVO) - Defense World
Thinking about buying stock in Mogo Inc, Rigetti Computing, Apte - GuruFocus.com
Ratio Examination: Aptevo Therapeutics Inc (APVO)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Company’s Banking Stock: Dissecting a -54.96% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated - AccessWire
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated - Yahoo Finance
Research Analysts’ New Coverage for August 10th (AGR, AGRX, AHPI, APVO, ATHX, ATRI, AUMN, AXDX, AY, BTX) - Defense World
Aptevo Therapeutics (NASDAQ:APVO) Posts Quarterly Earnings Results, Beats Expectations By $0.26 EPS - Defense World
Aptevo Therapeutics (NASDAQ:APVO) Earns Sell Rating from Analysts at StockNews.com - Defense World
APVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q2 2024 - MSN
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update - AccessWire
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update - StockTitan
Aptevo stockholders reject charter amendment, approve warrant terms - Investing.com India
Aptevo Therapeutics Inc (APVO) is a good investment, but the stock may be undervalued - US Post News
Aptevo stockholders reject charter amendment, approve warrant terms By Investing.com - Investing.com Canada
Bispecific Antibodies For Cancer Market size is set to grow by USD 314.3 million from 2024-2028, Increasing prevalence of cancer to boost the market growth, Technavio - The Malaysian Reserve
Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated at StockNews.com - Defense World
A closer look at Aptevo Therapeutics Inc (APVO)’s stock price trends - US Post News
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Growth in Short Interest - Defense World
Market Momentum: Aptevo Therapeutics Inc (APVO) Registers a -1.56 Decrease, Closing at 0.41 - The Dwinnex
Are Smart Investors Making the Right Decision? Aptevo Therapeutics Inc (APVO) - SETE News
Aptevo Therapeutics Inc (APVO) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Biotech Alert: Searches spiking for these stocks today - TipRanks
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday - InvestorPlace
Aptevo Therapeutics Inc ($APVO) Advances in Immuno-Oncology with Recent Offering and Warrant Amendments - Journal Transcript
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga
Understanding APVO stock ratios for better investment decisions - US Post News
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
S&P 500 Communication Services [Sector] (SRTS) QuotePress Release - The Globe and Mail
Finanzdaten der Aptevo Therapeutics Inc-Aktie (APVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.28%
1.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):